ESRRA (Estrogen-Related Receptor Alpha) is a nuclear receptor protein that regulates gene expression involved in energy metabolism, particularly the pathways cells use to generate fuel from nutrients. Despite its name, ESRRA is not directly activated by estrogen hormones but is structurally related to estrogen receptors and shares some overlapping regulatory targets.
Prior research had implicated ESRRA in several cancer types as a regulator of metabolic reprogramming, one of the hallmarks of cancer where tumor cells shift their energy production to support rapid growth. However, its specific role in uterine corpus endometrial carcinoma (UCEC), the most common gynecologic malignancy in high-income countries, had not been comprehensively characterized.
This study analyzed 552 UCEC tissue samples from The Cancer Genome Atlas (TCGA), a publicly available repository of cancer genomic and clinical data collected from patients across multiple institutions. By combining gene expression data, survival records, and functional experiments, the researchers assembled a multi-level picture of ESRRA's role in endometrial cancer.
The first question the researchers addressed was whether ESRRA expression is simply higher in cancer tissue than in normal tissue, which would be a prerequisite for it to function as a useful diagnostic marker. Analysis of TCGA data confirmed that both ESRRA mRNA (gene transcript) and protein levels were significantly elevated in UCEC tumor samples compared to normal endometrial tissue.
To quantify diagnostic utility, the researchers calculated the Area Under the Receiver Operating Characteristic Curve (ROC AUC) for ESRRA expression as a classifier of tumor versus normal tissue. The AUC was 0.854, which indicates strong discriminatory power. An AUC of 0.854 means that in 85.4% of randomly selected pairs of one cancer sample and one normal sample, ESRRA expression correctly identifies which is cancer.
This level of diagnostic performance, while not sufficient to use ESRRA expression as a standalone clinical test, suggests it could serve as a component of a multi-marker diagnostic panel or as a tissue marker for pathological confirmation of endometrial cancer diagnosis.
Beyond diagnosis, the researchers examined whether ESRRA expression at the time of tumor assessment predicts how patients fare over time. Using Kaplan-Meier survival curves, they found that UCEC patients with high ESRRA expression had significantly shorter overall survival than patients with low ESRRA expression, a difference that was statistically significant.
To confirm that this prognostic effect was not simply a consequence of ESRRA correlating with known risk factors (such as advanced tumor stage or high grade), the researchers performed multivariate Cox regression analysis, a statistical method that simultaneously accounts for multiple clinical variables and determines whether each variable independently predicts survival.
ESRRA emerged as an independent prognostic factor in this analysis, meaning its association with poor survival persisted after controlling for established prognostic variables. This independence is an important criterion for considering a biomarker clinically useful, as it means ESRRA provides information not already captured by existing clinical parameters such as stage, grade, and histotype.
To understand what ESRRA is doing biologically in endometrial tumors, the researchers performed Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA), computational methods that identify which biological pathways are activated in samples with high ESRRA expression compared to those with low expression.
The analyses revealed enrichment in metabolic pathways including glycolysis, the tricarboxylic acid (TCA) cycle, and the citrate cycle. These pathways are central to how cells produce energy and building blocks for growth. Many aggressive cancers show increased activity in precisely these pathways, a phenomenon sometimes called the Warburg effect, where cancer cells consume large amounts of glucose and other nutrients to fuel rapid proliferation.
The finding that ESRRA expression correlates with upregulation of these metabolic programs supports the hypothesis that ESRRA contributes to the metabolic reprogramming that gives endometrial cancer cells a growth advantage and may increase their resistance to some forms of therapy. It also positions ESRRA as a potential target for metabolic therapies being developed to starve cancer cells of the energy supply they depend on.
Observational correlations in patient data, however strong, cannot establish that ESRRA directly causes cancer cell behavior. To address causality, the researchers used siRNA (small interfering RNA), a molecular tool that silences a specific gene by targeting its messenger RNA for degradation, preventing the cell from making the corresponding protein.
When ESRRA was knocked down (silenced) in endometrial cancer cell lines using siRNA, the treated cells showed significantly reduced proliferation compared to control cells in which ESRRA remained active. This result demonstrates that ESRRA is not merely a bystander that happens to be expressed at high levels in aggressive tumors, but an active contributor to the growth machinery those tumors depend on.
This functional evidence upgrades ESRRA from a correlative biomarker to a potential therapeutic target. If a drug could safely inhibit ESRRA activity in tumor cells while sparing normal tissue, it might slow tumor growth. The fact that ESRRA belongs to the nuclear receptor family, a class of proteins historically tractable to drug design, makes this therapeutic hypothesis especially worth exploring.
The tumor immune microenvironment, the mix of immune cells present within and around a tumor, plays a major role in determining how well tumors respond to immunotherapy and other treatments. The researchers analyzed whether ESRRA expression in UCEC correlates with the abundance of different immune cell types as estimated from TCGA gene expression data.
ESRRA expression was positively correlated with neutrophil infiltration and negatively correlated with CD4-positive naive T cells, natural killer (NK) cells, and cancer-associated fibroblasts (CAF). A tumor microenvironment with fewer anti-tumor immune cells (T cells, NK cells) and more pro-tumor immune cells (neutrophils) is generally associated with worse prognosis and resistance to immunotherapy.
Additionally, ESRRA expression was found to be co-expressed with VEGF-b (Vascular Endothelial Growth Factor-b), a gene that promotes the growth of new blood vessels into tumors (angiogenesis). Together, these immune and vascular findings suggest that high ESRRA expression shapes a tumor microenvironment that favors tumor growth, immune evasion, and potentially resistance to therapy, providing several mechanistic links to the poor prognosis observed in high-ESRRA patients.